When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Última revisão: 19 Mar 2025
Última atualização: 18 Jan 2024

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • presença de fatores de risco
  • primeiro trimestre da gestação
  • sangramento vaginal
  • tamanho uterino incomum para a idade gestacional

Outros fatores diagnósticos

  • pré-eclâmpsia de início precoce
  • dispneia e desconforto respiratório
  • náuseas e vômitos intensos
  • taquicardia, tremor, insônia e diarreia
  • palidez
  • dor pélvica
  • sangramento uterino

Fatores de risco

  • extremidades etárias maternas
  • gravidez molar prévia
  • gordura e caroteno reduzidos na dieta

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • exame histológico do tecido placentário
  • gonadotrofina coriônica humana (hCG) sérica
  • ultrassonografia pélvica

Investigações a serem consideradas

  • Hemograma completo
  • tempo de protrombina (TP), tempo de tromboplastina parcial (TTP) séricos
  • perfil metabólico sérico
  • hormônio estimulante da tireoide (TSH) sérico
  • tipagem sanguínea com rastreamento de anticorpos
  • radiografia torácica

Algoritmo de tratamento

Colaboradores

Autores

Antonio Braga, MD

Associate Professor

Department of Obstetrics and Gynecology

Rio de Janeiro Federal University

Department of Maternal Child

Fluminense Federal University

Rio de Janeiro

Brazil

Declarações

AB is an author of references cited in this topic.

Kevin M. Elias, MD

Assistant Professor

Brigham and Women’s Hospital

Dana Farber Cancer Institute

New England Trophoblastic Disease Center

Division of Gynecologic Oncology

Department of Obstetrics, Gynecology and Reproductive Biology

Harvard Medical School

Boston

MA

Declarações

KME has been a paid consultant for AOA Dx and received research support from Aspira Women’s Health and Abcam, Inc. KME is an author of references cited in this topic.

Neil S. Horowitz, MD

Associate Professor

Brigham and Women’s Hospital

Dana Farber Cancer Institute

New England Trophoblastic Disease Center

Division of Gynecologic Oncology

Department of Obstetrics, Gynecology and Reproductive Biology

Harvard Medical School

Boston

MA

Declarações

NSH is an author of references cited in this topic.

Ross S. Berkowitz, MD

William H. Baker Professor of Gynecology

Brigham and Women’s Hospital

Dana Farber Cancer Institute

New England Trophoblastic Disease Center

Division of Gynecologic Oncology

Department of Obstetrics, Gynecology and Reproductive Biology

Harvard Medical School

Boston

MA

Declarações

RSB is an author of references cited in this topic.

Agradecimentos

Dr Ross S. Berkowitz, Dr Kevin M. Elias, Dr Neil S. Horowitz, and Dr Antonio Braga would like to gratefully acknowledge Dr John Soper and Dr Emma Rossi, previous contributors to this topic. JS and ER declare that they have no competing interests.

Revisores

Jane Stewart, PhD, MSc

Consultant Gynecologist

Subspecialist in Reproductive Medicine

Newcastle Fertility Centre at Life

Bioscience Centre

International Centre at Life

Newcastle upon Tyne

UK

Declarações

JS declares that she has no competing interests.

Philip Savage, PhD, FRCP

Consultant in Medical Oncology

Department of Medical Oncology

Charing Cross Hospital

London

UK

Declarações

PS declares that he has no competing interests.

Aparna Sundaram, DO, MBA, MPH

Physician Consultant

Preventive Medicine

Private Practice

Atlanta

GA

Declarações

AS declares that she has no competing interests.

O uso deste conteúdo está sujeito ao nosso aviso legal